Patrice Rioux - 26 Aug 2026 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Reporting relationship: Acting Chief Medical Officer
Issuer ticker: MNPR
Reported as of: 26 Aug 2026
Net transaction value: -$111
SEC form: 4
Accepted by SEC: 27 Aug 2026, 19:29:11 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Quan Vu, Attorney-in-fact

Key filing fact

Patrice Rioux filed Form 4 for Monopar Therapeutics (MNPR) on 27 Aug 2026.

Key facts

This page summarizes Patrice Rioux's Form 4 filing for Monopar Therapeutics (MNPR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Aug 2026, 19:29.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$111.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001241033 Primary reporting owner

RIOUX PATRICE

Relationship: Acting Chief Medical Officer
Address: 1000 SKOKIE BLVD SUITE 350, WILMETTE
Signature: /s/ Quan Vu, Attorney-in-fact
Signature date: 27 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MNPR transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,380
Change %: +37%
Price: $0.005000^*
Shares after: 5,066
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F1

MNPR transaction

Common Stock

Sale

Transaction value: $111
Shares: -1
Change %: -0.02%
Price: $111.26
Shares after: 5,065
Date: 26 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MNPR transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: +1,380
Change %
Price: $0.000000^*
Shares after: 0
Date: 26 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,380
Exercise price: $0.005000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.

Footnote F2

On December 15, 2016, the reporting person was granted stock options to purchase up to 1,400 shares of common stock vested: 238 shares on January 15, 2017; 224 shares on February 15, 2017; 238 shares on March 15, 2017; 224 shares on April 15, 2017; 238 shares on May 15, 2017; and 238 shares on June 15, 2017.